

Exploring Early Clinical Development through Innovative Drug Modalities

Chairs : Timothy Yu

Division of Genetics and Genomics, Boston Children's Hospital, USA / Harvard Medical School, USA

Takanori Yokota

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan

NFS-01-1 Progress towards interventional neurogenetics

Timothy Yu

Division of Genetics and Genomics, Boston Children's Hospital, USA / Harvard Medical School, USA

NFS-01-2 Developing a new HDO technology using morpholino oligomer to regulate gene expression

Tetsuya Nagata

NucleoTIDE and PepTIDE Drug Discovery Center, Tokyo Medical and Dental University, Japan
/ Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan

NFS-01-3 Establishing siRNA strategies for a single gene- or a single nucleotide-specific RNA interference

Kumiko Ui-Tei

Graduate School of Science, The University of Tokyo, Japan

NFS-01-4 Invention of an oral medication for genetic disorders caused by mis-splicing

Masatoshi Hagiwara

Department of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Japan

Progress in research on Parkinson's pathogenesis

Chairs : Takahiko Tokuda

National Institutes for Quantum Science and Technology (QST), Japan

Shinji Saiki

Department of Neurology, Institute of Medicine, University of Tsukuba, Japan

NFS-02-1 Introduction of research on PD pathogenesis

Shinji Saiki

Department of Neurology, Institute of Medicine, University of Tsukuba, Japan

NFS-02-2 The main stream "alpha-synuclein pathology"

Ayami Okuzumi

Department of Neurology, Faculty of Medicine, Juntendo University, Japan

NFS-02-3 Molecular mechanisms of mitochondria quality control and mitophagy underlying PD pathogenesis

Noriyuki Matsuda

Dept. Biomolecular Pathogenesis, Medical Research Inst., Tokyo Medical and Dental Univ., Japan

NFS-02-4 Autophagy as a guardian against ageing and age-related neurodegeneration

Viktor I. Korolchuk

Newcastle University, Biosciences Institute, Ageing Research, UK

NFS-03 Neuroscience Frontier Symposium 03

Web

AOCN2024

En

May 31 (Fri) 9:45 ~ 11:45

Room 01 (C Block 4F Hall C)

Co-evolution of imaging and fluid biomarkers toward stratification of neurological disorders

Chairs : Takashi Hanakawa

Kyoto University Graduate School of Medicine, Japan

Makoto Higuchi

National Institutes for Quantum Science and Technology, Japan

NFS-03-1 Biomarkers for Neurodegenerative Diseases

Ruben Smith

Lund University, Sweden

NFS-03-2 Parkinson's and Alzheimer's disease Dimensional Neuroimaging Initiative (PADNI)

Takashi Hanakawa

Kyoto University Graduate School of Medicine, Japan

NFS-03-3 Development of a Novel Plasma p-Tau181 Assay Reflecting Tau Tangle Pathology in Alzheimer's Disease

Kenji Tagai

National Institutes for Quantum and Radiological Science and Technology, Department of Functional Brain Imaging, Japan

NFS-03-4 Progress in fluid biomarkers in neurodegenerative disorders

Takahiko Tokuda

National Institutes for Quantum Science and Technology, Japan

NFS-03-5 Progress in imaging biomarkers in neurodegenerative disorders

Hirohisa Watanabe

Department of Neurology, Fujita Health University, School of Medicine, Japan

NFS-03-6 Fluid biomarkers in prodromal Parkinson's disease

Takeshi Ikeuchi

Brain Research Institute, Niigata University, Japan

A new era of cell and gene therapy for neurological diseases

Chairs : Hideyuki Okano

Keio University, Japan

Haruhisa Inoue

Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan

NFS-04-1 iPSCs-based Regenerative Therapy for Spinal Cord Injury

Hideyuki Okano

Keio University, Japan

NFS-04-2 Cellular transplantation therapy for toward ALS

Clive Svendsen

Board of Governors Regenerative Medicine Institute, USA

NFS-04-3 Mesenchymal stem cell therapy for Spinocerebellar degeneration

Chikafumi Yokoyama

REPROCELL Inc., Japan

NFS-04-4 Gene therapy in the field of experimental medicine of neurodegenerative diseases

Haruhisa Inoue

Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan

NFS-04-5 iPS cell-based therapy for Parkinson's disease

Jun Takahashi

Center for iPS Cell Research and Application, Japan

**Beyond prionoid propagation
-the toxicity mechanisms from inside and outside of cells-**

Chairs : Hitoshi Okazawa

Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Japan

Takafumi Hasegawa

Division of Neurology, Department of Neuroscience and Sensory Organs, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan

NFS-05-1 How does alpha-synuclein transfer from cell-to-cell?

- The role of endosomal trafficking

Takafumi Hasegawa

Division of Neurology, Department of Neuroscience and Sensory Organs, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan

NFS-05-2 Mechanisms of the initiation of alpha synuclein aggregation and the propagation

Kensuke Ikenaka

Osaka University Graduate School of Medicine, Japan

NFS-05-3 New mechanisms of toxicity from inside and outside of cells

Hitoshi Okazawa

Tokyo Medical and Dental University, Department of Neuropathology, Japan

NFS-05-4 Pathways of neuron demise in cerebellar ataxia and motor neuron demise: Leveraging insights from transcription dysregulation into novel therapy targets

Albert La Spada

University of California, Irvine, USA

1